Subscribe To
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report early data from its Phase 1b/2 combination study of TPST-1120 […] The post Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TP...
Read More
Content Topics
Tempest
Report
Early
Results
From
Global
Randomized
Phase
Combination
Tpst 1120
First line
Hepatocellular
Carcinoma
Forex
Posted: Apr 27 2023, 20:58
Author Name: forextv
Views: 092040